Most Oncology Brands Lose Before Launch Day — New ZoomRx Analysis of 40+ Drugs Quantifies the Awareness Gap That Predicts Commercial Failure

As oncology pipelines hit record highs, a new ZoomRx analysis shows most brands are already losing before they begin

Oncology brands that enter launch with below-average physician awareness are almost never able to close the gap. New data from ZoomRx “Laggards and Leaders" 2026 report shows that gap is measurable, predictable, and largely set 18 to 24 months before approval. In a market where unsuccessful launches carry lasting commercial consequences, the findings arrive at a moment when pre-launch investment decisions are under increasing scrutiny.

Key Findings

Across 44 oncology brands tracked by ZoomRx since 2020, a noticeable pattern emerges: pre-launch investment sequenced 18 to 24 months before approval — not post-launch promotion — is the primary determinant of commercial success, with top-performing brands entering Day 1 at 75% aided awareness compared to 55% for the lowest performers. Manufacturers that treat Top-of-Mind Awareness (TOMA) as a lagging metric may already be behind: TOMA movements precede prescribing shifts by months, and a plateau in the first 3 to 6 months post-launch is an early warning sign. Furthermore, below-norm brands enter Day 1 at 55% aided awareness versus 75% for top performers. That 25-point gap runs parallel through Month 48 and almost never closes. By Month 24, the Most Often Used (MOA) gap between top and below-norm brands reaches 58%. Brands that wait until launch day rarely catch up.

Varsha Sundaram, ZoomRx’s Product Lead for Brand Tracking, says, “The window to influence physician habit is not the first year post-launch. It is 12 to 24 months before it. By the time most launch teams act, the contest is already largely settled.”

The report also notes that when awareness fails to convert to prescribing, the root cause follows one of three diagnosable patterns: access barriers, positioning constraints, or differentiation gaps. Each of these patterns requires a fundamentally different response.

About the Report

Based on ZoomRx oncology-specific HCP survey data across 44 brands and 10+ oncology indications since 2020. Metrics include aided awareness, unaided awareness, TOMA, brand penetration, and MOU.

Download Report

Notes to Editors

ZoomRx identifies four priorities for launch teams: begin awareness-building 18 to 24 months before approval; track TOMA monthly as it moves before prescribing data does; diagnose the conversion barrier early; and treat the first six months as the decisive window. By Month 12, trajectory is set.

About ZoomRx

ZoomRx is a global life sciences consultancy serving 19 of the top 20 global biopharmaceutical companies.

Disclaimer: Research findings reflect the opinions of survey respondents at the time of data collection and are intended for informational purposes only. Results do not constitute medical, regulatory, or investment advice and should not be construed as predictive of future market conditions or commercial performance.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260506343027/en/